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Background
HIV-infected postmenopausal women have higher rates of bone loss than HIV negative women. We aimed to identify predictors
of body mass density (BMD) in HIV infected women entering menopause and to evaluate the pre- and post-menopausal BMD
change, with regard to tenofovir (TDF) use.
Methods
Women with at least one DEXA measurement were enrolled. The observation period was divided into: ‘‘Reproductive period’’,
‘‘Menopause transition period’’, ‘‘Early menopause period’’, ‘‘Late menopause period’’. BMD of the lumbar spine (L1-4)
and femur neck were measured by DEXA. Lowess smoothing curves were drawn to analyze impact of menopause and
TDF on BMD. Three different longitudinal linear regression models with random effects were built. Longitudinal
regression analysis fits cross sectional time series regression models and allows to analyze repeated measures for each
patient.
Results
Fifty-five women were included. Median age at enrollment was 46 years (IQ range 4449). Median observation period was 16
months (IQ range 8; 23) and 33 months (IQ range 23; 72) for pre- and post-menopausal respectively. At enrollment mean CD4
cell count was 553 cell/mL (9269.62) and HIV-VL was undetectable in 77.5% of patients: 6 women were not undergoing ART.
Most common backbone TDF/FTC (46.9%) and ABC/3TC (20.4%). At the time of inclusion in the cohort osteopenia and
ostoeporosis were present in 60% and 3.64%, respectively. At the time of last DEXA evaluation osteopenia and osteoporosis
were present in 78.18% and 36.36%, respectively.The impact of menopause on lumbar BMD was depicted (fig. 1) using a lowess
smoothing analysis according to current TDF exposure (as treated model). Lumbar BMD change predictors were years from
menopause and TDF current exposure in the ‘‘Early menopause period’’ and years from menopause, Baseline lumbar BMD, BMI
and vitD supplementation in the ‘‘Late menopause period’’.
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1Discussion
This is the first study analyzing BMD across menopause. BMD was stable in the pre-menopause period while BMD loss
characterized the post-menopause period. Traditional risk factors contributed to BMD change in the post -menopause period.
Current TDF exposure was independently associated with BMD change in the ‘‘Early menopause period’’only, but not confirmed
in the ‘‘Late menopause period’’, suggesting a compensating mechanism occurring after the second year post-menopause.
Transitional period Early menopause Late menopause
b 95% CI
p-
value b 95% CI
p-
value b 95% CI
p-
value
Years to (from*)
menopause
0.1 0.03; 0.01 0.407 0.01 0.02; 0.01 B0.001 0.1 0.2; 0.003 0.009
Baseline lumbar
BMD
0.0002 0.001; 0.003 0.078 0.0002 0.0001; 0.0004 0.074 0.9 0.701.09 B0.001
PTH 0.0005 0.001; 0.0004 0.280 0.0001 0.0004; 0.0002 0.535 0.0001 0.0002; 0.0002 0.800
BMI 0.003 0.005; 0.010 0.489 0.004 0.001; 0.010 0.142 0.008 0.002; 0.014 0.010
VitD
supplementation
0.003 0.05; 0.04 0.865 0.008 0.010; 0.026 0.392 0.03 0.001; 0.054 0.038
TDF current
exposure
0.03 0.07; 0.01 0.125 0.03 0.05; 0.01 0.012 0.04 0.09; 0.01 0.129
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